Subscribe
shutterstock_1425318470_photobyphm
Photobyphm / Shutterstock.com
5 March 2020AmericasSarah Morgan

Sanofi unit takes CSL to court over haemophilia therapy

Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix (coagulation factor IX (Recombinant), Fc fusion protein).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
Americas
USITC begins probe into CSL Behring
10 August 2017   The US International Trade Commission has instituted a probe into CSL Behring, a biopharmaceutical company.
Americas
French healthcare company makes $1.2bn AI drug discovery deal
18 August 2022   Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
Americas
USITC begins probe into CSL Behring
10 August 2017   The US International Trade Commission has instituted a probe into CSL Behring, a biopharmaceutical company.
Americas
French healthcare company makes $1.2bn AI drug discovery deal
18 August 2022   Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.

More on this story

Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
Americas
USITC begins probe into CSL Behring
10 August 2017   The US International Trade Commission has instituted a probe into CSL Behring, a biopharmaceutical company.
Americas
French healthcare company makes $1.2bn AI drug discovery deal
18 August 2022   Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?